Modalis Therapeutics Past Earnings Performance
Past criteria checks 0/6
Modalis Therapeutics's earnings have been declining at an average annual rate of -41.3%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been declining at an average rate of 111.5% per year.
Key information
-41.3%
Earnings growth rate
-38.3%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -111.5% |
| Return on equity | -74.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Modalis Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -1,870 | 240 | 1,583 |
| 30 Jun 24 | 0 | -2,138 | 232 | 1,912 |
| 31 Mar 24 | 0 | -2,316 | 245 | 2,081 |
| 31 Dec 23 | 0 | -2,391 | 248 | 2,102 |
| 30 Sep 23 | 0 | -2,974 | 233 | 1,972 |
| 30 Jun 23 | 0 | -2,960 | 221 | 1,989 |
| 31 Mar 23 | 0 | -2,796 | 219 | 1,862 |
| 31 Dec 22 | 40 | -2,702 | 213 | 1,861 |
| 30 Sep 22 | 40 | -1,866 | 199 | 1,806 |
| 30 Jun 22 | 40 | -1,530 | 197 | 1,438 |
| 31 Mar 22 | 41 | -1,377 | 192 | 1,267 |
| 31 Dec 21 | 1 | -738 | 196 | 1,009 |
| 30 Sep 21 | 3 | -415 | 199 | 676 |
| 30 Jun 21 | 6 | -457 | 209 | 676 |
| 31 Mar 21 | 329 | -129 | 195 | 634 |
| 31 Dec 20 | 342 | -448 | 174 | 531 |
| 31 Dec 19 | 644 | 140 | 184 | 303 |
| 31 Dec 18 | 65 | -217 | 62 | 217 |
Quality Earnings: 4883 is currently unprofitable.
Growing Profit Margin: 4883 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4883 is unprofitable, and losses have increased over the past 5 years at a rate of 41.3% per year.
Accelerating Growth: Unable to compare 4883's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4883 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 4883 has a negative Return on Equity (-74.44%), as it is currently unprofitable.